Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Rhea-AI Summary
Teva (NYSE: TEVA) will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan 13, 2026 at 8:15 AM PT to review its Pivot to Growth strategy, 2025 results and outlook through 2030. Key 2025 outlook: revenues $16.8–$17.0B, operating margin ~26.2%–27.1%, adjusted EBITDA $4.8–$5.0B, diluted EPS $2.55–$2.65, and free cash flow $1.6–$1.9B. Company expects additional contribution from duvakitug milestones (≈$500M revenue, ~$400M EBITDA, ~$500M FCF). Multi-year targets include low-single-digit revenue growth in 2027, operating profit ~30% in 2027, and free cash flow >$3.5B by 2030.
Positive
- 2025 revenue guidance of $16.8–$17.0B
- Targeted 2025 operating margin of ~26.2%–27.1%
- Adjusted EBITDA guidance of $4.8–$5.0B
- Free cash flow target of $1.6–$1.9B for 2025 and >$3.5B by 2030
- Planned net leverage reduction toward ~2.0–2.2x by 2027
Negative
- 2026 revenue expected to be flat to slightly down versus 2025
- 2025 outlook excludes duvakitug milestones; revenue at the lower point of range without them
- Material reliance on duvakitug milestones for incremental $400M–$500M in 2025 contributions
- Some metrics presented on a non‑GAAP basis (adjusted EBITDA, operating profit, free cash flow)
News Market Reaction – TEVA
On the day this news was published, TEVA gained 2.44%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.4% during that session. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $875M to the company's valuation, bringing the market cap to $36.72B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TEVA fell 1.54% while peers were mixed: UTHR -1.81%, RDY -0.45%, NBIX -0.15% versus VTRS +1.03% and TAK +0.31%, suggesting a stock-specific reaction to the guidance-heavy update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Conference notice | Neutral | +0.2% | Announced CEO presentation timing at J.P. Morgan healthcare conference. |
| Dec 24 | Ratings upgrade | Positive | +0.6% | Credit rating upgrade and positive outlook tied to deleveraging progress. |
| Dec 19 | Biosimilar settlement | Positive | +0.1% | Settlement setting U.S. entry date for AVT06 Eylea® biosimilar. |
| Dec 12 | Earnings call setup | Neutral | +1.1% | Scheduled Q4 2025 results release and conference call logistics. |
| Dec 12 | Aide Memoire post | Neutral | +1.1% | Published Q4 2025 Aide Memoire to guide expectations ahead of results. |
Recent news items, mostly informational or strategically positive, have been followed by modest positive price reactions, indicating generally constructive sentiment to company updates.
Over the last month, TEVA’s news flow featured conference participation, rating upgrades, and pipeline-related settlements. On Dec 24, 2025, rating agencies highlighted deleveraging and branded-medicine momentum, and the stock rose modestly. A biosimilar Eylea® settlement on Dec 19, 2025 also coincided with a small gain. Logistics updates around Q4 2025 results and the earlier J.P. Morgan conference notice likewise saw positive reactions. Today’s detailed 2025–2030 growth and margin framework builds directly on this "Pivot to Growth" narrative.
Market Pulse Summary
This announcement set out a comprehensive 2025–2030 framework, including 2025 revenues of $16.8–$17.0 billion, operating margins of about 26.2%–27.1%, and free cash flow of $1.6–$1.9 billion. Management also highlighted cumulative transformation savings of up to $700M and ambitions for mid-single-digit revenue CAGR by 2030. Investors may focus on delivery of pipeline milestones, progress toward the 2027 profitability and cash-flow targets, and how capital allocation supports an investment-grade profile.
Key Terms
adjusted ebitda financial
free cash flow financial
net leverage financial
investment-grade credit rating financial
late-stage innovative pipeline medical
ics/saba medical
anti-tl1a medical
anti-il-15 medical
AI-generated analysis. Not financial advice.
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)
TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva’s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company’s milestones achieved in 2025, transformative initiatives, and forward-looking outlook for 2026 and beyond.
Presentation Highlights:
- Pivot to Growth Strategy Progress: Teva is accelerating its Pivot to Growth strategy, focusing on transforming into a leading innovative biopharmaceutical company through late-stage innovative pipeline, fueled by its world-class generics business.
- Innovation at the Heart of Teva's Transformation: Teva's key innovative brands – AUSTEDO®, AJOVY® and UZEDY® – are already driving its growth and reshaping Teva's financial outlook. Teva’s clinical pipeline assets – olanzapine LAI, DARI (ICS/SABA), duvakitug (anti-TL1A), emrusolmin, and anti-IL-15 – are expected to drive Teva's long-term growth trajectory and further Teva’s transformation.
- 2025 Performance: Teva to provide its expected 2025 financial performance.
- 2026 and Beyond: In addition, Teva to provide forward-looking outlook for 2026 and beyond, underlining disciplined capital allocation and a commitment to securing an investment-grade credit rating.
Expected 2025 Performance
| $ billions, except EPS or as noted | 2025 Outlook | Expected 2025 performance relative to Outlook (excluding duvakitug milestones) | Additional contribution from expected duvakitug milestones |
| Revenues* | | Lower point of the range | |
| Operating Margin | ~ | Mid to high point of the range | ~ |
| Adjusted EBITDA | | Midpoint of the range | ~ |
| Tax Rate | | Lower point of the range | |
| Diluted EPS ($) | 2.55 - 2.65 | Higher point of the range | |
| Free Cash Flow** | | Higher point of the range | ~ |
| Net leverage | ~2.5x - 2.9x | Midpoint of the range | ~2.5x |
Path to achieving 2027 targets and additional 2030 targets
| $billionsor as noted | 2026 | 2027 | 2030 |
| Revenues* | Flat to slightly down vs. 2025 | Low-single digit growth | Mid-single digit CAGR |
| Operating Profit | Growing vs. 2025 | | > |
| Adjusted EBITDA | Growing vs. 2026 | Growing | |
| Free Cash Flow** | Growing vs. 2025 | > | > |
| Net Leverage | ~2.0-2.2x | <2x | <2x |
| Cumulative Transformation Programs Savings | ~ | ~ | |
Note: 2026 commentary compared to 2025 results excluding duvakitug milestones, except for net debt leverage calculation.
* Revenues presented on a GAAP basis; all other metrics presented on a non-GAAP basis.
** Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.
To access a live webcast of the presentation, visit Teva’s Investor Relations website at: https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to better health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Non-GAAP Financial Measures
This press release includes certain non-GAAP financial measures as defined by SEC rules. Management believes that such non-GAAP financial measures provide useful information to investors to facilitate their understanding of our business because the non-GAAP financial measures are used by Teva's management and board of directors, in conjunction with other performance metrics, to evaluate the operational performance of the company, to compare against the company's work plans and budgets, and ultimately to evaluate the performance of management; the company’s annual budgets are prepared on a non-GAAP basis; and senior management’s annual compensation is derived, in part, using these non-GAAP measures. Investors should consider the non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. In the case of the non-GAAP financial measures disclosed in this press release, we are not providing comparable forward looking guidance for GAAP financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measure because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP.
Teva Cautionary Note Regarding Forward Looking Statements
This Press Release and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial guidance, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” "outlook” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this document, in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned “Risk Factors” and “Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
| Teva Media Inquiries | TevaCommunicationsNorthAmerica@tevapharm.com |
| Teva Investor Relations Inquiries | TevaIR@Tevapharm.com |
FAQ
When and at what time will Teva (TEVA) present at the J.P. Morgan Healthcare Conference?
What revenue and EPS guidance did Teva (TEVA) provide for 2025?
How much incremental revenue and EBITDA does Teva (TEVA) expect from duvakitug milestones in 2025?
What are Teva's free cash flow and net leverage targets through 2027 and 2030?
What revenue growth does Teva (TEVA) forecast for 2027 and through 2030?
